{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pulmonary-embolism/management/confirmed-pulmonary-embolism/","result":{"pageContext":{"chapter":{"id":"cd66b55b-908e-56dc-811f-db55be20b710","slug":"confirmed-pulmonary-embolism","fullItemName":"Scenario: Confirmed pulmonary embolism","depth":2,"htmlHeader":"<!-- begin field 99f2d271-a1ef-46a7-a81d-a9abc93b19f3 --><h2>Scenario: Confirmed pulmonary embolism</h2><!-- end field 99f2d271-a1ef-46a7-a81d-a9abc93b19f3 -->","summary":"Covers the primary care follow up of people with confirmed PE, and briefly covers secondary care management.","htmlStringContent":"<!-- begin item 56aaa2bb-1096-4ebb-889f-43cf1a769ae8 --><!-- begin field 8142e534-e288-4621-b94b-acbc015816d5 --><p>From age 18 years onwards.</p><!-- end field 8142e534-e288-4621-b94b-acbc015816d5 --><!-- end item 56aaa2bb-1096-4ebb-889f-43cf1a769ae8 -->","topic":{"id":"322088c5-226e-5f2b-9fd2-2e2c0678abc1","topicId":"6b233aab-5318-4abb-96fa-1877e917ef2c","topicName":"Pulmonary embolism","slug":"pulmonary-embolism","lastRevised":"Last revised in October 2020","chapters":[{"id":"7d60ce89-0a3c-5336-a5d4-755eb5bfb2cd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99df9a07-7867-5283-b7c8-4589c8f6e029","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4da2d8a-f835-512f-b218-660b7fc61806","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c60f44ed-a5f4-566e-8718-a289b4d4e969","slug":"changes","fullItemName":"Changes"},{"id":"42a750f4-f134-55a8-a654-9c23ac2a3bfd","slug":"update","fullItemName":"Update"}]},{"id":"b8001d19-4cf2-5db4-b8b5-f082fbff4fbd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"52656989-9cf4-597c-8118-0fadcb887b21","slug":"goals","fullItemName":"Goals"},{"id":"cdd140ec-bd30-59e9-9777-c921159ea664","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c32413cc-9382-5aaa-b03b-95ed29a1b360","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c1a308a6-aa46-578f-98f1-ed7872474fb4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1629cec2-329a-5273-a313-15a0783d5b22","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4860e1f-9b8b-5f49-bdb5-fb068af327ab","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9e6802a1-b9c3-5fa9-b632-ef9712c1724b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"588bb6e5-794e-52df-9953-d91254204285","slug":"definition","fullItemName":"Definition"},{"id":"e2fbb90b-8419-52d9-bfd2-a9eab621be3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad38abd5-7668-59b3-828a-9edd427dbdd5","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"9b45f610-d957-50a3-9e85-019832acd145","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8e279dc8-2394-5073-8866-952291c0eee6","slug":"complications","fullItemName":"Complications"},{"id":"8be5980d-145d-5d9c-b255-f057579ce868","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c07c0850-0c27-58a8-96a8-96051968c076","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1db70c8e-a80c-587a-8e5e-5adf28878587","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"a71fc8ea-c1d7-5be5-a888-41b834fdca93","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f18a5246-939d-51ce-adb5-f6538871345a","fullItemName":"Management","slug":"management","subChapters":[{"id":"42f102a2-ceab-531f-880e-4075895d9c12","slug":"suspected-pulmonary-embolism","fullItemName":"Scenario: Suspected pulmonary embolism"},{"id":"cd66b55b-908e-56dc-811f-db55be20b710","slug":"confirmed-pulmonary-embolism","fullItemName":"Scenario: Confirmed pulmonary embolism"}]},{"id":"6ae8a494-48a2-5d60-b0f8-39dd5e02489b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8b812684-b06c-50e2-86d7-f012b792c674","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"f367e7b5-6b1b-5f42-9d57-a8edab35855f","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"c1bef62c-2c5a-5588-af53-1a0b4b26d3e3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3941fd8f-10fb-53d4-8dc1-3835ad3ca3e3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"26fc4bf9-2995-5109-9f1e-3ba9ad3dd2dd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1b2f1f8-81e2-5a3c-b454-2f63f66f6235","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"83fd7f66-6953-54a6-b55f-8d2858a82e97","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd9e363f-a674-594d-8bb9-8779d385e06a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"20c76427-9b00-5da0-bd68-6486385780f2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"96a22dd0-587f-5051-8263-acea49ba216b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f18a5246-939d-51ce-adb5-f6538871345a","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"fb90bf50-43c3-526b-b9ef-dd4cbf178c06","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field 28f0bff1-b90c-4b63-80e2-b2c46b97e310 --><h3>How should I follow up a person with confirmed pulmonary embolism?</h3><!-- end field 28f0bff1-b90c-4b63-80e2-b2c46b97e310 -->","summary":null,"htmlStringContent":"<!-- begin item a5977138-7f4b-4405-a210-f1e6a77f73fb --><!-- begin field 515f8063-2dea-46e7-8335-9335a80f9c5c --><p><strong>Following confirmation of pulmonary embolism (PE), and the initiation of <a class=\"topic-reference internal-reference\" href=\"/topics/pulmonary-embolism/management/confirmed-pulmonary-embolism/#secondary-care-treatment-options\">treatment</a>, in secondary care:</strong></p><ul><li><strong>Ensure adequate monitoring </strong><strong><strong>of</strong> anticoagulant treatment </strong>(warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>.</li><li><strong>Also ensure that the person is provided with:</strong><ul><li>An anticoagulant information booklet.</li><li>An anticoagulant alert card (which they should be advised to carry at all times).</li><li>Verbal and written information on oral anticoagulation treatment, including:<ul><li>How to use them and the duration of treatment.</li><li>Possible adverse effects and what to do if these occur.</li><li>The effects of other medications, foods, and alcohol on oral anticoagulation treatment.</li><li>Monitoring their anticoagulant treatment.</li><li>How anticoagulants may affect their dental treatment.</li><li>Taking anticoagulants if they are planning pregnancy or become pregnant.</li><li>How anticoagulants may affect activities, such as sports and travel.</li><li>When and how to seek medical help.</li></ul></li><li>Verbal and written information on PE.<ul><li>The British Lung Foundation website (<a href=\"https://www.blf.org.uk/\" data-hyperlink-id=\"4dc974e7-cc79-47b3-8839-a9d00179fb69\">www.blf.org.uk</a>) has patient information on <a href=\"https://www.blf.org.uk/support-for-you/pulmonary-embolism\" data-hyperlink-id=\"e17bdded-f512-4fab-b8c0-a9d00179fc2f\">Pulmonary embolism</a>. There is also a printable <a href=\"http://www.blf.org.uk/sites/default/files/IS22_pulmonary_embolism_v2_2015_2018.pdf\" data-hyperlink-id=\"0be18211-fa1b-4553-95ed-a9d00179fc3a\">patient information leaflet</a> on PE.</li><li>Detailed information on anticoagulant treatment, including adverse effects, drug interactions, advice during surgery and dental treatment, managing dosing errors, and where to obtain an alert care, are available in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/anticoagulation-oral/\">Anticoagulation - oral</a>.</li></ul></li></ul></li><li><strong>For people with </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/pulmonary-embolism/background-information/definition/\">unprovoked pulmonary embolism</a></strong><strong>:</strong><ul><li>Review the medical history and baseline blood test results including full blood count, renal and hepatic function, prothrombin time (PT) and activated partial thromboplastin time (APTT), and offer a physical examination for people who are not known to have cancer.<ul><li>Do not offer further investigations for cancer unless they have relevant clinical symptoms or signs. </li></ul></li><li>If it is planned to stop anticoagulation treatment, consider testing for:<ul><li>Antiphospholipid antibodies.</li><li>Hereditary thrombophilia in people who have a first-degree relative who has had deep vein thrombosis (DVT) or PE.</li></ul></li><li>Be aware that these tests can be affected by anticoagulants — specialist advice may be required.</li><li>Do not offer testing for hereditary thrombophilia to people who are continuing anticoagulation treatment.</li><li>Do not routinely offer thrombophilia testing to first-degree relatives of people with a history of DVT or PE and thrombophilia. </li></ul></li><li>Do not offer thrombophilia testing to people who have had provoked PE.</li></ul><!-- end field 515f8063-2dea-46e7-8335-9335a80f9c5c --><!-- end item a5977138-7f4b-4405-a210-f1e6a77f73fb -->","subChapters":[{"id":"07fe9229-a27f-5025-a9e2-e802b2489670","slug":"secondary-care-treatment-options","fullItemName":"Secondary care treatment options","depth":4,"htmlHeader":"<!-- begin field ca688ee6-f2c1-4c69-8504-a9c8012f4699 --><h4>Secondary care treatment options</h4><!-- end field ca688ee6-f2c1-4c69-8504-a9c8012f4699 -->","summary":null,"htmlStringContent":"<!-- begin item c426d98b-4ffe-4565-ba97-a9c8012f458a --><!-- begin field 96329566-4233-4ab8-9a30-a9c8012f4699 --><ul><li><strong>Pharmacological treatment </strong><strong>options for confirmed pulmonary embolism (PE) include:</strong><ul><li>Low molecular weight heparin (LMWH).</li><li>Fondaparinux.</li><li>Unfractionated heparin.</li><li>Oral anticoagulant treatment (warfarin, apixaban, or rivaroxaban).</li><li>LMWH followed by an oral anticoagulant (dabigatran or edoxaban).</li></ul></li><li><strong>Mechanical (or physical) interventions may be considered in some cases.</strong><ul><li>Inferior vena cava (IVC) filters are designed to trap fragmented thromboemboli from the deep leg veins en route to the pulmonary circulation (whilst preserving blood flow in the IVC filter).</li><li>Various filters are available and can be placed in the IVC filter on either a temporary basis (for example in people with PE who cannot have anticoagulation treatment) or a permanent basis (for example in people with recurrent PE despite adequate anticoagulation treatment after alternative treatments have been considered).</li></ul></li><li><strong>Thrombolytic therapy may be used to remove the embolic material from the pulmonary arteries by promoting lysis of blood clots.</strong><ul><li>The thrombolytic agent can either be given into a peripheral vein (systemic thrombolysis) or directly into the pulmonary arteries via a catheter (catheter-directed thrombolysis). It can also be combined with attempts to break up the thrombus by using mechanical devices inserted via a catheter into the major pulmonary arteries or attempting to aspirate the clot (pharmacomechanical thrombolysis).<ul><li>Pharmacological thrombolytics that have been used in the treatment of PE include streptokinase, urokinase, and rt-PA. These plasminogen activators stimulate the fibrinolytic system, leading to the lysis of blood clots. However, their mechanisms of action differ slightly: rt-PA is a fibrin-specific agent, preferentially activating plasminogen on the clot surface, whilst streptokinase and urokinase are non-selective agents.</li></ul></li><li>Open pulmonary embolectomy (surgical removal of clots in the pulmonary arteries) is an alternative used less commonly in modern practice. </li></ul></li><li><strong>The choice of treatment </strong>will depend on factors such as the licenced indication of the treatment, the presence of comorbidities, contraindication to treatment, and the preference of the person. Specialists will usually make clinical decisions on the duration of treatment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">National Clinical Guideline Centre, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">BTS, 2018</a>]</p><!-- end field 96329566-4233-4ab8-9a30-a9c8012f4699 --><!-- end item c426d98b-4ffe-4565-ba97-a9c8012f458a -->","subChapters":[]},{"id":"6017d4b9-9b46-56bb-8300-917b7a85c517","slug":"basis-for-recommendation-137","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c844c5d1-4aec-4c88-8a01-def2d30f15cd --><h4>Basis for recommendation</h4><!-- end field c844c5d1-4aec-4c88-8a01-def2d30f15cd -->","summary":null,"htmlStringContent":"<!-- begin item 137c1792-fb0f-4b8a-b699-99dd594a4412 --><!-- begin field 7164d45a-dc7a-4f29-bdde-1cc2756b201b --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing</em> <em>(full NICE guideline) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">National Clinical Guideline Centre, 2012</a>] and <em>Venous thromboembolic diseases: diagnosis, management and thrombophilia testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">NICE, 2020</a>].</p><h5>Investigations for undiagnosed cancer</h5><ul><li>Active cancer, with or without concurrent chemotherapy, is recognized as an independent and major <a class=\"topic-reference internal-reference\" href=\"/topics/pulmonary-embolism/background-information/risk-factors/\">risk factor</a> for venous thromboembolism (VTE).</li><li>Recent studies have shown there are differences in the optimum management of VTE between people with cancer and those without cancer. Thus, it is important to identify these people in order to manage their cancer at the earliest stage possible and also optimally manage their VTE to reduce the risk of a potentially serious recurrence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">National Clinical Guideline Centre, 2012</a>].</li></ul><h5>Thrombophilia testing</h5><ul><li>These recommendations are based on the expert opinion of the NICE guideline development group after consideration of evidence for thrombophilia prevalence, relative risk of VTE, recurrence for different types of thrombophilia, and effectiveness of treatment at preventing recurrences [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">National Clinical Guideline Centre, 2012</a>]. No clinical trials comparing testing against no testing were found.</li></ul><!-- end field 7164d45a-dc7a-4f29-bdde-1cc2756b201b --><!-- end item 137c1792-fb0f-4b8a-b699-99dd594a4412 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}